743 related articles for article (PubMed ID: 30203226)
1. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.
Hasselbalch H; Skov V; Kjær L; Larsen MK; Knudsen TA; Lucijanić M; Kusec R
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428587
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
[TBL] [Abstract][Full Text] [Related]
5. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
6. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
9. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Ellervik C; Larsen MK; Kjaer L; Skov V; Hasselbalch HC; Ottesen JT
Cancer Med; 2023 Feb; 12(4):4218-4226. PubMed ID: 36254099
[TBL] [Abstract][Full Text] [Related]
10. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L; Bose P; Verstovsek S
Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
[TBL] [Abstract][Full Text] [Related]
11. Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.
Yoon SY; Kim SY
Korean J Intern Med; 2023 Nov; 38(6):810-817. PubMed ID: 37939664
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.
Utke Rank C; Weis Bjerrum O; Larsen TS; Kjær L; de Stricker K; Riley CH; Hasselbalch HC
Leuk Lymphoma; 2016 Feb; 57(2):348-354. PubMed ID: 25956046
[TBL] [Abstract][Full Text] [Related]
13. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.
Hasselbalch HC; Skov V; Kjær L; Ellervik C; Poulsen A; Poulsen TD; Nielsen CH
Cytokine Growth Factor Rev; 2021 Aug; 60():28-45. PubMed ID: 33992887
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
[TBL] [Abstract][Full Text] [Related]
16. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
19. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hasselbalch HC
Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]